APO Research
Talk to an analyst

APO RESEARCH · REPORT

DTaP Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global DTaP Vaccine Market Outlook and Growth Opportunities 2026

19 December 2025199 pages

Choose your research edition.

Industry ResearchDTaP Vaccine Industry Research Report 2026111 pages · $2,950 USDIndustry Growth & TrendsGlobal DTaP Vaccine Industry Growth and Trends Forecast to 203272 pages · $3,450 USDMarket StructureGlobal DTaP Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032179 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal DTaP Vaccine Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal DTaP Vaccine Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global DTaP Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for DTaP Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for DTaP Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for DTaP Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the DTaP Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the DTaP Vaccine market include Merck, GlaxoSmithKline and Sanofi Pasteur, Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global DTaP Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of DTaP Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents DTaP Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the DTaP Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

DTaP Vaccine Segment by Company

Merck

GlaxoSmithKline

Sanofi Pasteur, Ltd.

DTaP Vaccine Segment by Type

Immune DTaP Vaccine

Therapy DTaP Vaccine

DTaP Vaccine Segment by Application

Adult

Pediatric

DTaP Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global DTaP Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions DTaP Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify DTaP Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze DTaP Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global DTaP Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of DTaP Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of DTaP Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the DTaP Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global DTaP Vaccine industry.

Chapter 3: Detailed analysis of DTaP Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of DTaP Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of DTaP Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. DTaP Vaccine Industry Trends Table 2. DTaP Vaccine Industry Drivers Table 3. DTaP Vaccine Industry Opportunities and Challenges Table 4. DTaP Vaccine Industry Restraints Table 5. Global DTaP Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global DTaP Vaccine Revenue Share by Company (2021-2026) Table 7. Global DTaP Vaccine Sales Volume by Company (K Units) & (2021-2026) Table 8. Global DTaP Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global DTaP Vaccine Average Price (US$/Unit) of Company (2021-2026) Table 10. Global DTaP Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global DTaP Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global DTaP Vaccine Company, Product Type & Application Table 13. Global DTaP Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global DTaP Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Immune DTaP Vaccine Table 18. Significant Companies of Therapy DTaP Vaccine Table 19. Global DTaP Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global DTaP Vaccine Sales Volume by Type (2021-2026) & (K Units) Table 21. Global DTaP Vaccine Sales Volume by Type (2027-2032) & (K Units) Table 22. Global DTaP Vaccine Sales Volume Share by Type (2021-2026) Table 23. Global DTaP Vaccine Sales Volume Share by Type (2027-2032) Table 24. Global DTaP Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global DTaP Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global DTaP Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global DTaP Vaccine Sales Value Share by Type (2021-2026) Table 28. Global DTaP Vaccine Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Adult Table 30. Significant Companies of Pediatric Table 31. Global DTaP Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global DTaP Vaccine Sales Volume by Application (2021-2026) & (K Units) Table 33. Global DTaP Vaccine Sales Volume by Application (2027-2032) & (K Units) Table 34. Global DTaP Vaccine Sales Volume Share by Application (2021-2026) Table 35. Global DTaP Vaccine Sales Volume Share by Application (2027-2032) Table 36. Global DTaP Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global DTaP Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global DTaP Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global DTaP Vaccine Sales Value Share by Application (2021-2026) Table 40. Global DTaP Vaccine Sales Value Share by Application (2027-2032) Table 41. Global DTaP Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global DTaP Vaccine Sales by Region (2021-2026) & (K Units) Table 43. Global DTaP Vaccine Sales Market Share by Region (2021-2026) Table 44. Global DTaP Vaccine Sales by Region (2027-2032) & (K Units) Table 45. Global DTaP Vaccine Sales Market Share by Region (2027-2032) Table 46. Global DTaP Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global DTaP Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global DTaP Vaccine Sales Value Share by Region (2021-2026) Table 49. Global DTaP Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global DTaP Vaccine Sales Value Share by Region (2027-2032) Table 51. Global DTaP Vaccine Market Average Price (US$/Unit) by Region (2021-2026) Table 52. Global DTaP Vaccine Market Average Price (US$/Unit) by Region (2027-2032) Table 53. Global DTaP Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Global DTaP Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global DTaP Vaccine Sales by Country (2021-2026) & (K Units) Table 56. Global DTaP Vaccine Sales Market Share by Country (2021-2026) Table 57. Global DTaP Vaccine Sales by Country (2027-2032) & (K Units) Table 58. Global DTaP Vaccine Sales Market Share by Country (2027-2032) Table 59. Global DTaP Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global DTaP Vaccine Sales Value Market Share by Country (2021-2026) Table 61. Global DTaP Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global DTaP Vaccine Sales Value Market Share by Country (2027-2032) Table 63. Merck Company Information Table 64. Merck Business Overview Table 65. Merck DTaP Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Merck DTaP Vaccine Product Portfolio Table 67. Merck Recent Development Table 68. GlaxoSmithKline Company Information Table 69. GlaxoSmithKline Business Overview Table 70. GlaxoSmithKline DTaP Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. GlaxoSmithKline DTaP Vaccine Product Portfolio Table 72. GlaxoSmithKline Recent Development Table 73. Sanofi Pasteur, Ltd. Company Information Table 74. Sanofi Pasteur, Ltd. Business Overview Table 75. Sanofi Pasteur, Ltd. DTaP Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Sanofi Pasteur, Ltd. DTaP Vaccine Product Portfolio Table 77. Sanofi Pasteur, Ltd. Recent Development Table 78. Key Raw Materials Table 79. Raw Materials Key Suppliers Table 80. DTaP Vaccine Distributors List Table 81. DTaP Vaccine Customers List Table 82. Research Programs/Design for This Report Table 83. Authors List of This Report Table 84. Secondary Sources Table 85. Primary Sources List of Figures Figure 1. DTaP Vaccine Product Image Figure 2. Global DTaP Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global DTaP Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global DTaP Vaccine Sales (2021-2032) & (K Units) Figure 5. Global DTaP Vaccine Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global DTaP Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Immune DTaP Vaccine Image Figure 10. Therapy DTaP Vaccine Image Figure 11. Global DTaP Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global DTaP Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global DTaP Vaccine Sales Volume Share by Type (2021-2032) Figure 14. Global DTaP Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global DTaP Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global DTaP Vaccine Sales Value Share by Type (2021-2032) Figure 17. Adult Image Figure 18. Pediatric Image Figure 19. Global DTaP Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global DTaP Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global DTaP Vaccine Sales Volume Share by Application (2021-2032) Figure 22. Global DTaP Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global DTaP Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global DTaP Vaccine Sales Value Share by Application (2021-2032) Figure 25. Global DTaP Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 26. Global DTaP Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global DTaP Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global DTaP Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America DTaP Vaccine Sales Value (2021-2032) & (US$ Million) Figure 30. North America DTaP Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe DTaP Vaccine Sales Value (2021-2032) & (US$ Million) Figure 32. Europe DTaP Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific DTaP Vaccine Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific DTaP Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America DTaP Vaccine Sales Value (2021-2032) & (US$ Million) Figure 36. South America DTaP Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa DTaP Vaccine Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa DTaP Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA DTaP Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA DTaP Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA DTaP Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada DTaP Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada DTaP Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada DTaP Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico DTaP Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico DTaP Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico DTaP Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany DTaP Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany DTaP Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany DTaP Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France DTaP Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France DTaP Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France DTaP Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. DTaP Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. DTaP Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. DTaP Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy DTaP Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy DTaP Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy DTaP Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain DTaP Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain DTaP Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain DTaP Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia DTaP Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia DTaP Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia DTaP Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands DTaP Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands DTaP Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands DTaP Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries DTaP Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries DTaP Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries DTaP Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China DTaP Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China DTaP Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China DTaP Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan DTaP Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan DTaP Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan DTaP Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea DTaP Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea DTaP Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea DTaP Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India DTaP Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India DTaP Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India DTaP Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia DTaP Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia DTaP Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia DTaP Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia DTaP Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia DTaP Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia DTaP Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil DTaP Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil DTaP Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil DTaP Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina DTaP Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina DTaP Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina DTaP Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile DTaP Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile DTaP Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile DTaP Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia DTaP Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia DTaP Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia DTaP Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru DTaP Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru DTaP Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru DTaP Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia DTaP Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia DTaP Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia DTaP Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel DTaP Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia DTaP Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia DTaP Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE DTaP Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE DTaP Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE DTaP Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey DTaP Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey DTaP Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey DTaP Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran DTaP Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran DTaP Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran DTaP Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt DTaP Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt DTaP Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt DTaP Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. DTaP Vaccine Value Chain Figure 124. Manufacturing Cost Structure Figure 125. DTaP Vaccine Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Immune DTaP Vaccine
  • Therapy DTaP Vaccine
Applications
  • Adult
  • Pediatric
Companies covered
  • Merck
  • GlaxoSmithKline
  • Sanofi Pasteur, Ltd.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global DTaP Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global DTaP Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global DTaP Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 DTaP Vaccine Market Dynamics
  1. 2.1 DTaP Vaccine Industry Trends
  2. 2.2 DTaP Vaccine Industry Drivers
  3. 2.3 DTaP Vaccine Industry Opportunities and Challenges
  4. 2.4 DTaP Vaccine Industry Restraints
3 DTaP Vaccine Market by Company
  1. 3.1 Global DTaP Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global DTaP Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global DTaP Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global DTaP Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global DTaP Vaccine Company Ranking (2024-2026)
  6. 3.6 Global DTaP Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global DTaP Vaccine Company Product Type and Application
  8. 3.8 Global DTaP Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global DTaP Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 DTaP Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 DTaP Vaccine Market by Type
  1. 4.1 DTaP Vaccine Type Introduction
  2. 4.1.1 Immune DTaP Vaccine
  3. 4.1.2 Therapy DTaP Vaccine
  4. 4.2 Global DTaP Vaccine Sales Volume by Type
  5. 4.2.1 Global DTaP Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global DTaP Vaccine Sales Volume by Type (2021-2032)
  7. 4.2.3 Global DTaP Vaccine Sales Volume Share by Type (2021-2032)
  8. 4.3 Global DTaP Vaccine Sales Value by Type
  9. 4.3.1 Global DTaP Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global DTaP Vaccine Sales Value by Type (2021-2032)
  11. 4.3.3 Global DTaP Vaccine Sales Value Share by Type (2021-2032)
5 DTaP Vaccine Market by Application
  1. 5.1 DTaP Vaccine Application Introduction
  2. 5.1.1 Adult
  3. 5.1.2 Pediatric
  4. 5.2 Global DTaP Vaccine Sales Volume by Application
  5. 5.2.1 Global DTaP Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global DTaP Vaccine Sales Volume by Application (2021-2032)
  7. 5.2.3 Global DTaP Vaccine Sales Volume Share by Application (2021-2032)
  8. 5.3 Global DTaP Vaccine Sales Value by Application
  9. 5.3.1 Global DTaP Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global DTaP Vaccine Sales Value by Application (2021-2032)
  11. 5.3.3 Global DTaP Vaccine Sales Value Share by Application (2021-2032)
6 DTaP Vaccine Regional Sales and Value Analysis
  1. 6.1 Global DTaP Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global DTaP Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global DTaP Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global DTaP Vaccine Sales by Region (2027-2032)
  5. 6.3 Global DTaP Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global DTaP Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global DTaP Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global DTaP Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global DTaP Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America DTaP Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America DTaP Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe DTaP Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe DTaP Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific DTaP Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific DTaP Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America DTaP Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America DTaP Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa DTaP Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa DTaP Vaccine Sales Value Share by Country, 2025 VS 2032
7 DTaP Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global DTaP Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global DTaP Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global DTaP Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global DTaP Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global DTaP Vaccine Sales by Country (2027-2032)
  6. 7.4 Global DTaP Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global DTaP Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global DTaP Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA DTaP Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA DTaP Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA DTaP Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada DTaP Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada DTaP Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada DTaP Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico DTaP Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico DTaP Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico DTaP Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany DTaP Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany DTaP Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany DTaP Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France DTaP Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France DTaP Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France DTaP Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. DTaP Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. DTaP Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. DTaP Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy DTaP Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy DTaP Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy DTaP Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain DTaP Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain DTaP Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain DTaP Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia DTaP Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia DTaP Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia DTaP Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands DTaP Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands DTaP Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands DTaP Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries DTaP Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries DTaP Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries DTaP Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China DTaP Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China DTaP Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China DTaP Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan DTaP Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan DTaP Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan DTaP Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea DTaP Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea DTaP Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea DTaP Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India DTaP Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India DTaP Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India DTaP Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia DTaP Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia DTaP Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia DTaP Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia DTaP Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia DTaP Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia DTaP Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil DTaP Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil DTaP Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil DTaP Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina DTaP Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina DTaP Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina DTaP Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile DTaP Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile DTaP Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile DTaP Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia DTaP Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia DTaP Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia DTaP Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru DTaP Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru DTaP Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru DTaP Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia DTaP Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia DTaP Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia DTaP Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel DTaP Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel DTaP Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel DTaP Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE DTaP Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE DTaP Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE DTaP Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey DTaP Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey DTaP Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey DTaP Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran DTaP Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran DTaP Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran DTaP Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt DTaP Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt DTaP Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt DTaP Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck
  2. 8.1.1 Merck Company Information
  3. 8.1.2 Merck Business Overview
  4. 8.1.3 Merck DTaP Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Merck DTaP Vaccine Product Portfolio
  6. 8.1.5 Merck Recent Developments
  7. 8.2 GlaxoSmithKline
  8. 8.2.1 GlaxoSmithKline Company Information
  9. 8.2.2 GlaxoSmithKline Business Overview
  10. 8.2.3 GlaxoSmithKline DTaP Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 GlaxoSmithKline DTaP Vaccine Product Portfolio
  12. 8.2.5 GlaxoSmithKline Recent Developments
  13. 8.3 Sanofi Pasteur, Ltd.
  14. 8.3.1 Sanofi Pasteur, Ltd. Company Information
  15. 8.3.2 Sanofi Pasteur, Ltd. Business Overview
  16. 8.3.3 Sanofi Pasteur, Ltd. DTaP Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Pasteur, Ltd. DTaP Vaccine Product Portfolio
  18. 8.3.5 Sanofi Pasteur, Ltd. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 DTaP Vaccine Value Chain Analysis
  2. 9.1.1 DTaP Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 DTaP Vaccine Sales Mode & Process
  6. 9.2 DTaP Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 DTaP Vaccine Distributors
  9. 9.2.3 DTaP Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst